The iShares Select U.S. REIT ETF (ICF 0.33%) keeps costs lower and has outperformed over five years, while the FlexShares Global Quality Real Estate Index Fund(GQRE 0.52%)offers global diversification and a much higher yield, though at a higher fee. Both ICF and GQRE aim to deliver real estate exposure through baskets of REITs, but their approaches diverge: ICF focuses exclusively on U.S. names, w...
The iShares Select U.S. REIT ETF (ICF 0.33%) keeps costs lower and has outperformed over five years, while the FlexShares Global Quality Real Estate Index Fund(GQRE 0.52%)offers global diversification and a much higher yield, though at a higher fee. Both ICF and GQRE aim to deliver real estate exposure through baskets of REITs, but their approaches diverge: ICF focuses exclusively on U.S. names, while GQRE spans global markets with a quality filter. This comparison looks at cost, performance, risk, and what each fund actually owns. Snapshot (cost & size) Metric ICF GQRE Issuer IShares FlexShares Expense ratio 0.32% 0.46% 1-yr return (as of 2026-03-16) 4.2% 6.4% Dividend yield 2.7% 4.5% Beta 0.98 0.93 AUM $2.0 billion $355.0 million Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. ICF looks more affordable on fees, while GQRE commands a premium but compensates with a higher payout, offering a 1.8 percentage point yield advantage for income-focused investors. Performance & risk comparison Metric ICF GQRE Max drawdown (5 y) -34.75% -35.08% Growth of $1,000 over 5 years $1,117 $1,013 What's inside GQRE tracks a global real estate index, holding 219 securities with a strict quality overlay and 100% real estate allocation, and has been around for more than 12 years. Its top holdings include American Tower Corp Reit(AMT 0.71%), Prologis Inc Reit(PLD 0.92%), and Welltower Inc(WELL 0.21%), with no unusual quirks or leverage resets, making it a straightforward global REIT play. By contrast, ICF focuses solely on the U.S. real estate sector and holds just 30 names, heavily weighted toward large, established REITs such as Equinix Reit Inc (EQIX 0.61%), Welltower Inc, and American Tower Reit Corp. Both funds are pure real estate, but ICF is far more concentrated and U.S.-centric. For more guidance on ETF investing, check out the full guide at this link. ...
alexsl Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics ( MLTX ) to Buy from Neutral, citing a “clearer path to approval” for the Swiss biotech’s lead candidate, sonelokimab, targeted at a skin disorder known as hidradenitis suppurativa in the U.S. Analyst Qize Ding argued that while regulatory filings for sonelokimab are not yet complete, its “biggest regulatory hurdle is out of the w...
alexsl Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics ( MLTX ) to Buy from Neutral, citing a “clearer path to approval” for the Swiss biotech’s lead candidate, sonelokimab, targeted at a skin disorder known as hidradenitis suppurativa in the U.S. Analyst Qize Ding argued that while regulatory filings for sonelokimab are not yet complete, its “biggest regulatory hurdle is out of the way" after, according to the company, the FDA said that no additional trials are required for the drug based on its existing Phase 2 and 3 trial data. “Our base case is that SLK is unlikely to face major hurdles in the FDA review process and that its overall profile is likely to be similar to the best-in-class approved therapy in HS,” the analyst added, raising his price target on the stock to $40 from $12 per share. Ding noted that MoonLake ( MLTX ) hasn’t changed its prior guidance on the timing for approval and launch of sonelokimab. He raised his peak sales estimates for the drug to $3.2B from $2.7B compared to $2.1B in the consensus, arguing that it “remains an attractive asset for large biopharma.” More on MoonLake Immunotherapeutics MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript MoonLake nabs FDA Fast Track status for rare inflammatory disorder asset MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval
Apple Inc. (NASDAQ: AAPL) is the world’s most valuable publicly traded company, commanding a market capitalization of $3.73 trillion as of March 2026. As a cornerstone of the Magnificent 7 and a generational wealth compounder with returns exceeding 900% over the past decade, Apple stock remains one of the most widely held and closely analyzed equities on Wall Street. But with a forward P/E ratio n...
Apple Inc. (NASDAQ: AAPL) is the world’s most valuable publicly traded company, commanding a market capitalization of $3.73 trillion as of March 2026. As a cornerstone of the Magnificent 7 and a generational wealth compounder with returns exceeding 900% over the past decade, Apple stock remains one of the most widely held and closely analyzed equities on Wall Street. But with a forward P/E ratio north of 29x, investors need to understand whether AAPL can justify its premium valuation heading into the next phase of growth. This comprehensive guide breaks down everything investors need to know about Apple stock in 2026 — from earnings performance and analyst price targets to the company’s AI strategy, Services growth engine, and iPhone super-cycle dynamics. Whether you’re evaluating AAPL as a buy, hold, or sell, this analysis provides the data-driven insights to make an informed decision. Apple Stock Overview: Key Metrics at a Glance 🔗 Before diving into the analysis, here are the essential financial metrics every Apple investor should know: Metric Value Ticker AAPL (NASDAQ) Stock Price ~$250 (March 2026) Market Cap $3.73 trillion Trailing P/E 31.75 Forward P/E 29.04 TTM Revenue $435.6 billion TTM EPS $7.87 Dividend Yield 0.42% 52-Week Range $169 – $275 Active Devices 2.5 billion Analyst Consensus Buy (avg. target ~$298) Q1 FY2026 Earnings: Record-Breaking Quarter 🔗 Apple’s fiscal first quarter of 2026 (ending December 2025) delivered results that silenced many skeptics. The company reported revenue of $143.8 billion, a 16% year-over-year increase and a record for any quarter in Apple’s history. Earnings per share came in at $2.84, beating the consensus estimate of $2.67 by 6.3%. The standout performer was iPhone, which generated $85.3 billion in revenue — a staggering 23% increase year-over-year. CEO Tim Cook highlighted “double-digit growth in switchers” from Android and record iPhone upgrades during the earnings call, with demand described as “simply staggering.” G...
nortonrsx/iStock via Getty Images Without a doubt, the most jarring market trend of 2026 is the speed at which enterprise software stocks have crashed to multi-year lows. In the space of just a few months, investors flipped their opinion on AI as a tailwind to business and are now fearing the displacement risk it will have across industries, particularly in enterprise SaaS companies. ServiceTitan ...
nortonrsx/iStock via Getty Images Without a doubt, the most jarring market trend of 2026 is the speed at which enterprise software stocks have crashed to multi-year lows. In the space of just a few months, investors flipped their opinion on AI as a tailwind to business and are now fearing the displacement risk it will have across industries, particularly in enterprise SaaS companies. ServiceTitan ( TTAN ), the vertical software company that addresses trades businesses (such as home technicians, electricians, and plumbers), has been among the hardest-hit companies. Since the start of the year, shares of ServiceTitan have lost more than 30% of their value, and relative to highs near $130 notched last May, the stock is down by nearly half. The key question for investors is, is ServiceTitan's decline commensurate with its fundamental performance, or is the selloff overdone? Data by YCharts I last wrote a "B uy" article on ServiceTitan in January, when the stock was trading just shy of $100 per share. Since then, ServiceTitan has lost ~30% of its value. Yes, there are elements that we need to be careful about here: GTV and revenue are decelerating, as ServiceTitan is being held down by a tougher macroeconomy that is sidelining many consumers from home improvements. That said, I think ServiceTitan's lower valuation, plus its consistent margin improvements, helps to compensate us for slower growth. I'm reiterating my "Buy" rating here. It's useful for us to kick off the discussion with an overview of ServiceTitan and the possibility for AI to take over its core use cases. In short, I think it's unlikely. The chart below is a good refresher on all the core features that ServiceTitan offers to its clients. The company positions itself as a one-stop shop for tradespeople, offering marketing and CRM tools alongside scheduling, dispatch, pricing, and payment offerings. ServiceTitan platform capabilities (ServiceTitan Q4 earnings deck) Yes, it's true that relative to many other ...
Investors with an interest in Food - Miscellaneous stocks have likely encountered both US Foods (USFD) and Celsius Holdings Inc. (CELH). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value cat...
Investors with an interest in Food - Miscellaneous stocks have likely encountered both US Foods (USFD) and Celsius Holdings Inc. (CELH). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits. US Foods has a Zacks Rank of #2 (Buy), while Celsius Holdings Inc. has a Zacks Rank of #4 (Sell) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that USFD has an improving earnings outlook. But this is only part of the picture for value investors. Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels. Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years. USFD currently has a forward P/E ratio of 17.67, while CELH has a forward P/E of 31.82. We also note that USFD has a PEG ratio of 0.86. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. CELH currently has a PEG ratio of 3.05. Another notable valuation metric for USFD is its P/B ratio of 3.57. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, CELH has a P/B of 16.20. These are just a few of the metrics contributing to USFD's Value grade of A and CE...
Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Align Technology (ALGN) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value cat...
Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Align Technology (ALGN) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Right now, both Align Technology and West Pharmaceutical Services are sporting a Zacks Rank of #2 (Buy). Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. But this is just one factor that value investors are interested in. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value. ALGN currently has a forward P/E ratio of 15.38, while WST has a forward P/E of 30.42. We also note that ALGN has a PEG ratio of 1.53. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. WST currently has a PEG ratio of 2.56. Another notable valuation metric for ALGN is its P/B ratio of 3.06. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, WST has a P/B ...
Investors interested in Retail - Apparel and Shoes stocks are likely familiar with Deckers (DECK) and Industria de Diseno Textil SA (IDEXY). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system...
Investors interested in Retail - Apparel and Shoes stocks are likely familiar with Deckers (DECK) and Industria de Diseno Textil SA (IDEXY). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Currently, Deckers has a Zacks Rank of #1 (Strong Buy), while Industria de Diseno Textil SA has a Zacks Rank of #3 (Hold). This means that DECK's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value. DECK currently has a forward P/E ratio of 15.21, while IDEXY has a forward P/E of 23.43. We also note that DECK has a PEG ratio of 2.38. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. IDEXY currently has a PEG ratio of 2.96. Another notable valuation metric for DECK is its P/B ratio of 5.69. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, IDEXY has a P/B of 8.35. These are just a few of the metrics contributing to DECK's Value grade of B and IDEXY'...
CBS News Investigation Uncovers Massive Medicare Hospice Fraud In L.A. County Authored by Bryan Hyde via American Greatness, An investigation by CBS News has discovered massive Medicare fraud at more than 700 out of 1,800 licensed hospice providers in Los Angeles County. The scam utilizes stolen Medicare numbers to fraudulently enroll healthy seniors in hospice with fake terminal diagnoses, billin...
CBS News Investigation Uncovers Massive Medicare Hospice Fraud In L.A. County Authored by Bryan Hyde via American Greatness, An investigation by CBS News has discovered massive Medicare fraud at more than 700 out of 1,800 licensed hospice providers in Los Angeles County. The scam utilizes stolen Medicare numbers to fraudulently enroll healthy seniors in hospice with fake terminal diagnoses, billing Medicare an average of $29,000 per patient without delivering care, to the tune of hundreds of millions of taxpayer dollars. CALIFORNIA HOSPICE FRAUD: There's a stretch in Los Angeles with 500 registered hospice companies within just three miles of each other. And 89 in a single building. But when we visited, we found empty offices, piled-up mail, and phone lines dead. Watch CBS News' exclusive… pic.twitter.com/ydb8v0RqxE — CBS News (@CBSNews) March 10, 2026 About 31 percent of hospice and home health companies in the U.S. are registered in L.A. County but when investigators visited the addresses listed, they found no clinics, patients or healthcare workers. Instead they found multiple red flags, including multiple hospices in one building, high rates of terminally ill patients later discharged alive, excessive billing, and staff shared across multiple companies. The California state auditor had sounded the alarm three years ago, saying that Los Angeles County had seen the number of hospice companies increase more than six times the national average, relative to its elderly population. Let’s put this in perspective. The population of residents age 65 or over in California is estimated at 6.3 million while Florida estimates its population of 65+ residents at 4.9 million. Public records show 2,279 Medicare-certified hospice organizations in California with just 208 such Medicare-certified organizations in Florida. This raises serious questions as to why California would have more than 10 times the number of Medicare-certified hospice organizations than Florida when it has l...
Investing.com -- Long-only investors shifted decisively toward non-U.S. equities in February, according to a new note from Bank of America. Quant strategist Nigel Tupper wrote that “long-only funds globally bought non-US stocks but sold US stocks,” marking a clear divergence in regional positioning. BofA noted that combined active and passive funds recorded their largest inflows into Emerging Mark...
Investing.com -- Long-only investors shifted decisively toward non-U.S. equities in February, according to a new note from Bank of America. Quant strategist Nigel Tupper wrote that “long-only funds globally bought non-US stocks but sold US stocks,” marking a clear divergence in regional positioning. BofA noted that combined active and passive funds recorded their largest inflows into Emerging Markets, purchasing over $17.6 billion, followed by Asia Pac at over $14.9 billion. In contrast, the biggest outflows were in the United States, where funds sold $69.5 billion in shares. By sector, the strongest buying occurred in Consumer Staples at more than $7.9 billion and Materials at over $5 billion, while Software and Media saw heavy selling of $17.7 billion and $11 billion, respectively. The note said the world’s largest long-only stock purchases last month included Walmart, AbbVie, Roche and ASML, while major sales included AstraZeneca, Microsoft, Apple and NVIDIA. BofA highlighted that the most widely held stocks globally by long-only funds remain TSMC at 92 percent ownership, followed by ARM at 88 percent, Microsoft at 84 percent, NVIDIA at 74 percent and Tencent at 72 percent. The bank also said “Crowded Positives,” which are names combining high ownership and positive “Triple Momentum”, continue to outperform. These currently include Broadcom, TSMC, Samsung Electronics, Micron Technology, SK Hynix and Eli Lilly. Related articles Long-only funds are buying non-US stocks, BofA says 5 reasons why Jefferies thinks Meta’s pullback is a buying opportunity Wolfe Research outlines eight risks that could spark stock declines in 2026
Apple has hired thousands of people each year over the last decade or so as its businesses have continued to grow. From research and development to meeting customers at its retail stores, Apple’s employees are in demand. Apple also rewards its employees well, and some are compensated with ...
Apple has hired thousands of people each year over the last decade or so as its businesses have continued to grow. From research and development to meeting customers at its retail stores, Apple’s employees are in demand. Apple also rewards its employees well, and some are compensated with ...
Image source: The Motley Fool. Thursday, March 19, 2026 at 9 a.m. ET CALL PARTICIPANTS Chairman & Chief Executive Officer — Efraim Grinberg Executive Vice President & Chief Financial Officer — Sallie A. DeMarsilis TAKEAWAYS Revenue -- $191.6 million for the quarter, up 5.6%; full-year sales rose 2.7% to $671.3 million, supported by U.S. wholesale and retail growth. -- $191.6 million for the quarte...
Image source: The Motley Fool. Thursday, March 19, 2026 at 9 a.m. ET CALL PARTICIPANTS Chairman & Chief Executive Officer — Efraim Grinberg Executive Vice President & Chief Financial Officer — Sallie A. DeMarsilis TAKEAWAYS Revenue -- $191.6 million for the quarter, up 5.6%; full-year sales rose 2.7% to $671.3 million, supported by U.S. wholesale and retail growth. -- $191.6 million for the quarter, up 5.6%; full-year sales rose 2.7% to $671.3 million, supported by U.S. wholesale and retail growth. U.S. Net Sales -- Increased 11.2% in the quarter; year-end U.S. sales were up 4.3%, driven primarily by volume rather than price. -- Increased 11.2% in the quarter; year-end U.S. sales were up 4.3%, driven primarily by volume rather than price. International Net Sales -- Rose 1% in the quarter, with notable growth in Europe and Mexico, but declined 5.9% on a constant currency basis due to weakness in the Middle East. -- Rose 1% in the quarter, with notable growth in Europe and Mexico, but declined 5.9% on a constant currency basis due to weakness in the Middle East. Gross Margin -- Held nearly flat at 54.1% in the quarter (vs. 54.2% prior year); full-year gross margin was 54.2%, up 20 basis points, despite a 150 basis-point tariff headwind. -- Held nearly flat at 54.1% in the quarter (vs. 54.2% prior year); full-year gross margin was 54.2%, up 20 basis points, despite a 150 basis-point tariff headwind. Operating Income -- Quarterly adjusted operating income rose 6.2% to $14.4 million; full-year climbed 28.7% to $34.8 million. -- Quarterly adjusted operating income rose 6.2% to $14.4 million; full-year climbed 28.7% to $34.8 million. Net Income -- $13 million, or $0.57 per diluted share, in the quarter versus $11.5 million, or $0.51 per share, last year; full-year net income was $30.4 million, or $1.34 per share. -- $13 million, or $0.57 per diluted share, in the quarter versus $11.5 million, or $0.51 per share, last year; full-year net income was $30.4 million, or $1.34 p...
Nextech Invest, Ltd. disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it reduced its stake in Kymera Therapeutics (NASDAQ:KYMR) by 62,013 shares, an estimated $4.19 million trade based on quarterly average pricing. According to the SEC filing dated February 17, 2026, Nextech Invest, Ltd. sold 62,013 shares of Kymera Therapeutics in the fourth quarter. The esti...
Nextech Invest, Ltd. disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it reduced its stake in Kymera Therapeutics (NASDAQ:KYMR) by 62,013 shares, an estimated $4.19 million trade based on quarterly average pricing. According to the SEC filing dated February 17, 2026, Nextech Invest, Ltd. sold 62,013 shares of Kymera Therapeutics in the fourth quarter. The estimated transaction value was $4.19 million, calculated using the average closing price during the quarter. The quarter-end value of the position increased by $2.41 million, a figure reflecting both trading activity and changes in the stock’s price. Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline. The company’s strategy centers on first-in-class therapies for diseases with high unmet medical need, leveraging a robust research platform to drive next-generation drug discovery in biotechnology. Continue reading
'Movement never lies': 100 years of the Martha Graham Dance Company toggle caption Marty Lederhandler/AP "Movement never lies" and "Look for the truth." Legendary dance artist Martha Graham lived by these rules, which she learned from her father when she was a little girl. She used them to create the Martha Graham Dance Company, which this year celebrates its 100th anniversary. To celebrate, the c...
'Movement never lies': 100 years of the Martha Graham Dance Company toggle caption Marty Lederhandler/AP "Movement never lies" and "Look for the truth." Legendary dance artist Martha Graham lived by these rules, which she learned from her father when she was a little girl. She used them to create the Martha Graham Dance Company, which this year celebrates its 100th anniversary. To celebrate, the company is on an international tour. Graham was a force in the dance world: a choreographer, founder of a school in addition to her renowned company, and a leading dancer herself. She was a diplomat and a rebel, a free-thinker and an "animal of discipline," as Mikhail Baryshnikov once put it. Sponsor Message In the early 20th century, when Graham founded her company, most people thought of dance as Swan Lake and Giselle. "Decorative, escapist, imaginary princesses and swans and flowers," said Janet Eilber, a former member of the company and its current artistic director. "And she wanted to dance about real human beings, real human challenges." toggle caption Baron/Hulton Archive/Getty Images Graham wanted to use dance to tell American stories, which at the time was a revolutionary idea, when so much of American cultural life was focused on Europe. The characters in her Appalachian Spring, for example, are Pennsylvania pioneers: women in bonnets and long dresses, a smitten young couple and a preacher. Created in the 1940s, with music by American composer Aaron Copland, it's a spirited ballet partly intended to inspire hope as World War II was coming to an end. Graham knew the landscape well, having grown up in Pennsylvania coal country, which she described as "completely bleak" in her autobiography. She had to wear veils over her clothes to keep off the coal dust. toggle caption NYC Dance Project When she was 14, she and her family moved to California, traveling across the country by train. Graham was thrilled. She wrote in her book that her years there "became a time of ligh...
Key Points VNQI offers broader international diversification and a higher dividend yield compared to VNQ VNQ is substantially larger, more liquid, and has outperformed over the past five years Both ETFs have similar risk profiles, but their top holdings and sector concentrations differ markedly 10 stocks we like better than Vanguard Real Estate ETF › Vanguard Global ex-U.S. Real Estate ETF (NASDAQ...
Key Points VNQI offers broader international diversification and a higher dividend yield compared to VNQ VNQ is substantially larger, more liquid, and has outperformed over the past five years Both ETFs have similar risk profiles, but their top holdings and sector concentrations differ markedly 10 stocks we like better than Vanguard Real Estate ETF › Vanguard Global ex-U.S. Real Estate ETF (NASDAQ:VNQI) and Vanguard Real Estate ETF (NYSEMKT:VNQ) share similar costs and risk levels, but VNQI delivers a higher yield and global diversification, while VNQ stands out for its massive assets under management and superior five-year total return. Both Vanguard funds give investors access to real estate equities, but they focus on different geographies: VNQI provides exposure to non-U.S. property markets, while VNQ targets U.S.-listed real estate investment trusts (REITs). This comparison examines cost, yield, performance, risk, sector makeup, and practical differences to help clarify which may better fit a portfolio seeking real estate diversification. Snapshot (cost & size) Metric VNQI VNQ Issuer Vanguard Vanguard Expense ratio 0.12% 0.13% 1-yr return (as of 2026-03-16) 11.7% 1.3% Dividend yield 4.6% 3.7% Beta 0.71 1.02 AUM $4.2 billion $69.6 billion Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. VNQI and VNQ are nearly identical on fees, with VNQI a hair more affordable, but VNQI also delivers a higher dividend yield, which may appeal to those seeking income from global real estate. Performance & risk comparison Metric VNQI VNQ Max drawdown (5 y) -35.76% -34.48% Growth of $1,000 over 5 years $817 $1,003 What's inside VNQ invests in 158 U.S.-listed REITs, with a portfolio heavily concentrated in real estate (98%), and small allocations to communication services and technology. Top holdings include Welltower Inc(NYSE:WELL), Prologis Inc(NYSE:PLD), ...